Alkem Laboratories Moat Analysis: Score & Risks
Alkem Laboratories Ltd.
A first-pass moat teardown of Alkem Laboratories Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it.
First-pass narrow read — primary edge in Network Effects. Provisional, single-pass evidence.
Alkem Laboratories Ltd. scores 5.04 on MoatSCORE 6.0 — a narrow moat in Pharma. This is a first-pass note: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued.
Seven dimensions of moat
Ordered by contribution. Each dimension carries a verified filing quote, graded [M] mechanism or [O] outcome.
“Behind every success are our people. With over 21,000+ employees, including 12,500+ medical representatives, Alkem's culture remains rooted in empowerment, agility, and shared purpose.”
“We have outperformed IPM in six key focused therapies: Gastro-intestinal grew by ~1.8X, VMN ~1.6X, Pain ~1.7X, Anti-Diabetic ~1.4X, Respiratory ~1.6X and Derma ~2.0X.”
“By combining a North America-based delivery engine with an India-led R&D and cost leadership, Enzene is building a differentiated model that offers global biotech firms the best of both worlds.”
“What sets Enzene apart is not just technical strength, but also its growing global client base across human health and animal health, including pharma partners in the US, Europe, and India.”
“Talent density across R&D, regulatory, quality, and precision manufacturing”
D8 rating: ADEQUATE. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed.
The barrier gate — first-pass
Effective barrier 6.0 — clears the gate. First-pass estimate.
Deep two-pass review. This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read.
The barrier gate. A firmer replication or bypass estimate is the most likely thing to shift the band.
Adverse events. Any governance, regulatory or funding shock captured in D8 could re-rate the fade window.
Where this note fits. This company is one of 113 Indian companies we have scored for moat durability — 88 narrow, 25 narrow-trending-wide, none wide. The full ranked read: Wide-Moat Stocks in India: We Scored 113 Companies and Found None. Every score, dimension by dimension, is free in the Moat Screener.
Member discussion